| scholarly article | Q13442814 |
| P50 | author | David J. Conway | Q30347162 |
| P2093 | author name string | Kevin K A Tetteh | |
| P2860 | cites work | Detecting signatures of balancing selection to identify targets of anti-parasite immunity | Q37751523 |
| Plasmodium falciparum: gp195 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in vitro | Q38888200 | ||
| A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses | Q38952180 | ||
| Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity | Q39006938 | ||
| Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen | Q39518664 | ||
| Cross-sectional study of specific antibodies to a polymorphic Plasmodium falciparum antigen and of parasite antigen genotypes in school children on the slope of Mount Cameroon | Q43558702 | ||
| Development of a malaria T-cell vaccine for blood stage immunity | Q44259737 | ||
| Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys | Q44676194 | ||
| Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species | Q47857319 | ||
| MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking | Q47862670 | ||
| Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen | Q47874795 | ||
| A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria | Q47885076 | ||
| Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition | Q47897203 | ||
| A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea | Q47901914 | ||
| Towards validated assays for key immunological outcomes in malaria vaccine development | Q47971724 | ||
| Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). | Q48024331 | ||
| Antigenicity of recombinant proteins derived from Plasmodium falciparum merozoite surface protein 1. | Q48036521 | ||
| In vivo induction of type 1 and 2 immune responses against protein antigens | Q73312323 | ||
| Molecular identification of a malaria merozoite surface sheddase | Q24811597 | ||
| Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1 | Q28743564 | ||
| Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response | Q28748610 | ||
| High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model | Q28749979 | ||
| RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection | Q33251913 | ||
| Population diversity and antibody selective pressure to Plasmodium falciparum MSP1 block2 locus in an African malaria-endemic setting | Q33510819 | ||
| In vitro growth-inhibitory activity and malaria risk in a cohort study in mali | Q33613892 | ||
| Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response | Q33613937 | ||
| Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development | Q33654911 | ||
| Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion | Q33761687 | ||
| Characterization of conserved T- and B-cell epitopes in plasmodium falciparum major merozoite surface protein 1 | Q34004267 | ||
| Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial | Q34006332 | ||
| Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development | Q34069682 | ||
| In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response | Q34260615 | ||
| Regulated maturation of malaria merozoite surface protein‐1 is essential for parasite growth | Q34369560 | ||
| Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria | Q34855814 | ||
| Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection | Q35504908 | ||
| Genetic diversity in the Block 2 region of the merozoite surface protein 1 (MSP-1) of Plasmodium falciparum: additional complexity and selection and convergence in fragment size polymorphism | Q35754182 | ||
| Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. | Q36114395 | ||
| Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1 | Q36313955 | ||
| A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies | Q36371697 | ||
| Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria | Q36594057 | ||
| A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits | Q36710710 | ||
| The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. | Q37559892 | ||
| The malaria merozoite, forty years on. | Q37568142 | ||
| Antibodies to the N-terminal block 2 of plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria | Q37582802 | ||
| P433 | issue | 44 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| P304 | page(s) | 7811-7817 | |
| P577 | publication date | 2011-08-04 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1. | |
| P478 | volume | 29 |
| Q57059017 | An expanded global inventory of allelic variation in the most extremely polymorphic region of Plasmodium falciparum merozoite surface protein 1 provided by short read sequence data |
| Q37264614 | Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity |
| Q59795795 | Diversity analysis of MSP1 identifies conserved epitope organization in block 2 amidst high sequence variability in Indian Plasmodium falciparum isolates |
| Q37704962 | Genetic diversity of MSP1 Block 2 of Plasmodium vivax isolates from Manaus (central Brazilian Amazon). |
| Q90435715 | Genetic diversity of Plasmodium falciparum and genetic profile in children affected by uncomplicated malaria in Cameroon |
| Q37352099 | High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms |
| Q38159694 | N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine |
| Q26853267 | Paths to a malaria vaccine illuminated by parasite genomics |
Search more.